Alza Ditropan XL
Executive Summary
Abbott co-promotion of overactive bladder therapy oxybutynin ends as part of merger termination agreement. Abbott also will not have right of first negotiation to co-promote Alza's once-daily attention deficit/ hyperactivity disorder therapy Concerta (methylphenidate). The termination will not involve payments by either company